After nearly 23% decline over the quarter, Medincell stock gains 2.5%
The Montpellier-based biopharmaceutical company rebounds during the session, in a Paris market oriented downward. The stock stands out from the SBF 120 index and regains altitude after a difficult quarter.
A rebound that contrasts with the SBF 120 trend and rises above the 20-day moving average
Medincell stock gains 2.61% to €22.78 at midday, while the SBF 120 falls 0.9% and the CAC 40 drops 0.99%. The stock ranks among the strongest gains in the index, behind Nanobiotix, ID Logistics Group and Valneva during the session. This movement allows it to rise above its 20-day moving average (€22.58), with a gap of 0.89%.
The MA50 (€23.87) remains 4.57% above the price, and the MA200 (€24.79) 8.11% higher. The RSI at 45 remains neutral. Today's gain only offsets a small part of the quarterly decline of 22.83%, and weekly performance remains at -1.04%.
A stock trading at 54 times the expected earnings of the following fiscal year
In terms of valuation, the consensus of analysts surveyed places the projected P/E ratio at approximately 455.6 times current fiscal year earnings and 54.2 times those of the following fiscal year. The company develops long-acting injectable treatments, including UZEDY, marketed by Teva. On September 21, Teva presented new clinical data on its olanzapine based on Medincell's BEPO technology, with an FDA decision expected by end of 2026. From a technical perspective, the stock is evolving between support at €21.40 and resistance at €24.88, representing a downside margin of 5.9% and an upside margin of 9.2%.
